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Abstract (199 words) 
RNA helicases of the DEAD-box family of proteins are involved in many aspects 
of RNA metabolism from transcription to RNA decay but most of them have also been 
shown to be multi-functional. A member DDX5 has been shown to interact with the 
RNA-dependent RNA polymerase (NS5B) of hepatitis C virus. Here, we report the 
presence of two independent NS5B binding sites in DDX5, one located at the N terminus 
and another at the C terminus.  The N-terminal fragment of DDX5, DDX5-N, was 
crystallized and the structure of domain 1 of DDX5 shows typical features found in the 
structures of other DEAD-box helicases. DDX5-N contains the highly variable N 
terminal region (NTR) of unknown function and the crystal structure reveals structural 
elements in part of the NTR, namely residues 52-78. This region forms an extensive loop 
and an -helix. From co-immunoprecipitation experiments, the NTR of DDX5-N was 
observed to auto-inhibit its interaction with NS5B.  Interestingly, the -helix in NTR is 
essential for this auto-inhibition and seems to mediate the interaction between the highly 
flexible 1-60 residues in NTR and NS5B binding site in DDX5-N.  Furthermore, NMR 
investigations reveal that there is a direct interaction between DDX5 and NS5B in vitro. 
 
 







Hepatitis C is an infectious disease affecting an estimated 150-200 million people 
worldwide. Infection is caused by the hepatitis C virus (HCV), which can often lead to 
cirrhosis, steatosis, and hepatocellular carcinoma.  HCV is an enveloped, single stranded 
positive-sense RNA virus in the family Flaviviridae [1]. The viral genome is encoded by 
three structural proteins (core, E1 and E2) and seven non-structural proteins (p7, NS2, 
NS3, NS4A, NS4B, NS5A and NS5B). NS3, a serine protease and RNA helicase, along 
with NS5B, an RNA-dependent RNA polymerase, are key enzymes required for HCV 
replication and therefore common targets for antiviral agents. Viral replication requires 
interaction between RNA, viral and host proteins [1]. NS5B has been shown to interact 
with a growing number of host proteins including eukaryotic initiation factor 4AII [2], 
cellular vesicle membrane transport protein VAP-33 [3], nucleolar phosphoprotein 
nucleolin I [4] and the DEAD (Asp-Glu-Ala-Asp) box RNA helicase DDX5 [5]. 
DDX5, also referred to as p68, is a nuclear prototypic member of the DEAD-box 
family of proteins. The DEAD-box family belongs to helicase superfamily 2 (SF2), 
which also includes DEAH, DExH and DExD families (see recent reviews by [6-8]). 
DEAD-box helicases share nine conserved motifs that are clustered in a central region 
and possess highly variable amino and carboxyl termini. The central region of DEAD-
box helicases region can be organized into two domains; domain 1 consists of motifs Q, I 
(Walker A), II (Walker B, DEAD box), Ia, Ib and III while domain 2 consists of motifs 
IV, V, and VI. Motif Q, which is unique to DEAD-box helicases, forms the nucleotide 
binding site together with motifs I and II. Motif III has been implicated in linking ATP 
binding and hydrolysis with the helical activity. The remaining motifs are involved in 
RNA binding. The functions of the variable N and C terminal regions are not fully 
characterized but they are thought to interact with RNA substrates or co-factors so as to 
confer specificity or fine modulation of function. 
DDX5 was first identified by its immunological cross-reactivity to a monoclonal 
antibody to the large T antigen of simian virus 40 [9]. Co-purification of DDX5 with 
splicesomes initially suggested a role in RNA splicing and this was subsequently 
confirmed when DDX5 was shown to be an essential splicing protein acting at the U1 
snRNA-5’ splice site [10]. DDX5 has also been shown to be involved in RNA export, 
ribosome assembly, translation and RNA degradation [6, 11-12]. However, there is a 
growing body of evidence suggesting DDX5 has an additional role as a transcriptional 
co-activator for different genes [13]. 
DDX5 has been shown to interact with HCV NS5B and the knockdown of DDX5 
by RNA interference caused a reduction in the transcription of negative-strand HCV 
RNA [5]. Furthermore, the over-expression of NS5B has been shown to result in the 
redistribution of DDX5 from the nucleus to the cytoplasm [5] and interestingly, DDX5 
was also found to have undergone similar translocation in HCV infected cells [14]. In 
addition, single nucleotide polymorphisms in DDX5 gene have been shown to be 
significantly associated with increased risk of advanced fibrosis in HCV patients [15]. 
While the precise role of DDX5 in HCV infection has yet to be defined, these studies 
suggest that it may play an important role in HCV replication. 
In order to gain an understanding into the mechanism of interaction between 
DDX5 and NS5B, we expressed DDX5(1-305 amino acids (aa)) and obtained the crystal 
structure of part of the variable N terminal region (NTR) and domain 1 (residues 52 to 
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304) at 2.7 Å resolution.  The residues in DDX5 involved in the interaction with NS5B 
were also evaluated by using site-directed mutagenesis and co-immunoprecipitation 
experiments.  Furthermore, NMR investigations were performed to determine if there is a 
direct interaction between DDX5 and NS5B. 
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Materials and Methods 
Mammalian expression constructs 
The open reading frame encoding human DDX5 was amplified from a spleen 
cDNA expression library [5]. DDX5 was cloned into pXJ40myc, a myc-tagged plasmid 
derived from pXJ40 [16]. DDX5 deletion and substitution mutants were generated by 
polymerase chain reaction. NS5B was amplified from the cDNA of HCV-S1 of genotype 
1b [17], and cloned into pXJ40flag, a flag-tagged plasmid derived from pXJ40 [16]. 
 
Transfection, co-immunoprecipitation and Western Blot analysis 
Huh-7 cells (human hepatoma, JCRB Cell Bank) were cultured in Dulbecco’s 
Minimal Eagle’s medium supplemented with 10 % fetal bovine serum (HyClone 
Laboratories) and antibiotics, penicillin at 10 Units/ml and streptomycin at 100 μg/ml 
(Sigma), and maintained at 37°C in 5% carbon dioxide. 
Plasmids were transiently transfected into Huh-7 cells plated in 6-cm2 tissue 
culture dishes using Lipofectamine (Invitrogen), according to the manufacturer’s 
instruction. The cells were harvested ~24 h post-transfection and lysed in 150 μl of RIPA 
buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% (v/v) NP-40, 0.5% (w/v) 
deoxycholic acid, 0.005% (w/v) SDS and 1 mM PMSF) and subjected to three cycles of 
freezing and thawing. The cell lysates were spun down at 16 000 g for 20 min at 4°C to 
remove cell debris.  
For co-immunoprecipitation, cell lysates were first incubated with 2 μg of anti-
myc polyclonal antibody (Santa Cruz) for 1 h at room temperature before mixing with 20 
μl pre-washed Protein A-agarose beads (Roche). The mixtures were left to incubate 
overnight with agitation at 4°C. The protein-bound beads were then washed 4 times with 
1 ml RIPA buffer. 5X SDS loading buffer (0.3 M Tris-HCl, pH 6.8, 5% (w/v) SDS, 50% 
(v/v) glycerol, 0.1 M dithiothreitol (DTT) and 0.1% (w/v) bromophenol blue) was added 
to the washed beads. The bound proteins were eluted from the beads by boiling the 
samples at 100°C for 5 min. Similarly, 5X SDS loading buffer was added to aliquots of 
cell lysates before immunoprecipitation and the samples were boiled at 100°C for 5 min.  
All protein samples were resolved on SDS- polyacrylamide gels, transferred onto 
Hybond-C nitrocellulose membranes (GE Healthcare) and blocked with 5% non-fat milk 
in PBS with 0.05% (v/v) Tween-20. The membranes were then incubated with primary 
antibodies (either anti-myc polyclonal antibody (Santa Cruz) or anti-flag monoclonal 
antibody (Sigma) or anti-flag polyclonal antibody (Sigma)) followed by secondary 
antibodies conjugated with horseradish peroxidase. The proteins were then visualized 
with the aid of SuperSignal® West Pico Substrate Kit (Pierce). The chemiluminescent 
protein signals were captured on Amersham Hyperfilm™ (GE Healthcare). 
 
Expression and purification of bacterially expressed DDX5(1-305aa) 
The N-terminal domain of DDX5 (residues 1-305) was expressed as a glutathione 
S-transferease (GST) (pGEX6p1, GE Heathcare) fusion protein. GST-DDX5(1-305aa) 
was expressed in Escherichia coli BL21-CodonPlus-RIL (Stratagene). Cultures were 
grown at 37oC in Terrific-Broth medium and on reaching an OD600 of 0.8, cells were 
cooled to 16oC and induced with isopropyl β-D-1-thiogalactopyranoside to a final 
concentration of 0.2 mM. After an incubation period of 24 h, cells were harvested. 
Bacterial pellets were re-suspended in lysis buffer (50 mM Tris-HCl, pH 7.4, 300 mM 
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NaCl and 2 mM DTT) supplemented with Complete Protease Inhibitor (Roche). For 
purification, cells were subjected to sonication. The lysate was cleared by centrifugation 
and loaded onto a 5 ml glutathione sepharose column (GE Healthcare) pre-equilibrated 
with lysis buffer. The column was washed to remove unbound material. Removal of the 
GST tag from the N-terminal of DDX5(1-305aa) was achieved by proteolytic cleavage 
using recombinant 3C protease (GE Healthcare). Cleaved protein was further purified by 
size-exclusion chromatography using Superdex S200 column (GE Healthcare) pre-
equilibrated in lysis buffer. Purified DDX5(1-305aa) was concentrated to 12 mg/ml using 
Amicon Ultra (10 kDa cutoff, Millipore). 
 
Crystallization and data collection 
Crystals of recombinant DDX5(1-315aa) (12 mg/ml) were obtained at 15oC using 
the sitting-drop vapour diffusion method from 1 : 1 µl  of protein and precipitant 
containing 2% (v/v) Tacsimate (pH 4.0), 0.1 M Bis-Tris (pH 6.5) and 20% (w/v) 
polyethylene glycol (PEG) 3350. Crystals were transferred to a reservoir solution 
containing the precipitant with the addition of 30 % glycerol, before flash freezing in 
liquid nitrogen. 
X-ray diffraction data from a single crystal of DDX5(1-305aa) was collected at 
the National Synchrotron Radiation Research Center (NSRRC, Taiwan) on beamline 
13B1. Raw data were integrated and scaled using the HKL2000 program suite [18]. 
 
Structure determination and refinement 
The structure of DDX5(1-305aa) was determined by the molecular replacement 
method, using the structure of domain 1 of DDX3X ([19] Protein Data Bank (PDB) code 
2I4I) as the search model, with the program Molrep from CCP4 suite [20]. The model 
was refined with CNS [21], and multiple rounds of manual fitting with the program O 
[22] using 2Fo-Fc and Fo-Fc electron density maps. The refined model consists of 57 
water molecules, with a final R and Rfree of 27% and 29% respectively. There is 1 
molecule in the asymmetric unit with 253 residues. The stereochemistry of DDX5(1-
305aa) was checked with PROCHECK [23]. The refinement statistics are summarized in 
Table 1. 
 
In vitro translation and GST pull-down assay 
pXJ40myc-DDX5(61-614aa) and pXJ40flag-NS5B plasmids were used as 
templates to produce the 35S-labeled proteins using the TNT reticulocyte lysate system 
(Promega), according to the manufacturer’s protocol. 
30 μg of GST and GST fusion proteins bound on glutathione sepharose beads 
were washed three times with GST pull-down buffer (PBS with 0.5% (v/v) Triton X-100, 
0.5% (v/v) NP40, 1 mM EDTA, 1 mM EGTA and 0.4 mM PMSF). 20 μl of 35S-labeled 
proteins, diluted with 80 μl GST pull-down buffer were added to the beads and the 
mixtures were incubated at room temperature for 1 h. The beads were then washed 4 
times with GST pull-down buffer. 5X SDS loading buffer was added to the beads and the 
bound proteins were eluted from the beads by boiling at 100°C for 5 min. The samples 
were resolved on a 10% SDS-polyacrylamide gel. The resolved gel was soaked in a 
solution of 45% methanol and 10% acetic acid for 30 min and then placed in Amplify™ 
solution (GE Healthcare) for 30 min. The gel was placed on a piece of filter paper, 
 7
covered with cling wrap and dried for 1 h at 80°C in a gel drier. The radiolabelled signals 
were captured on Amersham Hyperfilm™ (GE Healthcare). 
 
Expression and purification of recombinant proteins for CD and NMR studies 
The gene encoding the 570-residue NS5B was PCRed out from the pXJ40flag-
NS5B plasmid, which contains NS5B of HCV genotype 1b [5], and then cloned into 
pET32a.  The gene encoding DDX5(61-305aa) was excised by restriction enzyme 
digestion from the mammalian expression vector described above and cloned into 
pGEX6p1 vector (GE Heathcare).  These two bacterial expression vectors were 
transformed into Escherichia coli BL21 (DE3) Star (invitrogen) cells. For expression of 
recombinant proteins, cells were grown in Luria-Bertani medium in the presence of 
ampicillin (100 mg/ml) at 37 °C to reach the absorbance of 0.6 at 600 nm and 
subsequently induced with respective optimized isopropyl β-D-1-thiogalactopyranoside 
concentrations.  Harvested cells were resuspended and  lysed by sonication in lysis buffer 
(50 mM Tris, pH 7.5, 500 mM NaCl, 10% glycerol, 20 mM imidazole, 10 mM 2-
mercaptoethanol) containing protease inhibitor cocktail (Roche). His-tagged NS5B and 
GST-tagged DDX5(61-305aa) proteins were purified by Ni2+-affinity chromatography 
(Qiagen) and glutathione sepharose chromatography (GE Healthcare) respectively under 
native conditions. The recombinant proteins were released from the fused tags by in-gel 
cleavage with either thrombin (for NS5B) or 3C protease (for DDX5(61-305aa)) and 
further purified by size-exclusion chromatography using Superdex S200 column (GE 
Healthcare). The production of the isotope-labeled DDX5(61-305aa) protein for NMR 
studies followed a similar procedure except that the bacteria were grown in M9 medium 
with the addition of (15NH4)2SO4 for 15N labeling as previously described [24-25]. The 
concentration of protein samples was determined by the spectroscopic method in the 
presence of denaturant [24-26]. 
 
CD and NMR experiments 
All CD experiments were carried out in a Jasco J-810 spectropolarimeter (Jasco 
Corporation, Tokyo, Japan) as previously described [25] at 25 ºC. The protein 
concentration is 20 µM in 2 mM phosphate buffer (pH 6.5) for all far-UV CD 
experiments.  
NMR samples were prepared in 10 mM phosphate buffer in the presence of 10 
mM DTT (pH 6.5). All NMR data were collected at 25 °C on an 800-MHz Bruker 
Avance spectrometer equipped with a shielded cryoprobe as previously described [24-
25].  For Heteronuclear Single Quantum Coherence (HSQC) characterization of the 15N-
labeled DDX5(61-305aa), samples were prepared at a protein concentration of 100 µM. 
For NMR characterization of the binding interaction of DDX5(61-305aa) to NS5B, one-
dimensional 1H NMR spectra of the DDX5(61-305aa) protein were acquired at a protein 
concentration of 20 µM in the absence or presence of the unlabeled NS5B at molar ratios 
of 1:1; 1:2 and 1:3 (DDX5:NS5B).  NMR data were processed with NMRpipe [27] and 
analyzed with NMRview [28].  
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Results  
DDX5 contains two independent NS5B binding sites  
To determine which domain(s) in DDX5 are involved in the interaction with 
NS5B, coimmunoprecipitation experiments were performed using deletion mutants of 
DDX5.  Flag-tagged NS5B was expressed in Huh-7, a liver cell line that supports HCV 
replication, together with myc-tagged DDX5 proteins (Figure 1). The results showed that 
two non-overlapping fragments of DDX5, DDX5(61-305aa) and DDX5(306-614aa), 
bound to NS5B, indicating that there are two independent NS5B binding sites in DDX5.  
In contrast, DDX5(1-305aa) showed no significant binding to NS5B indicating that the 
deletion of the N-terminal 60 residues of DDX5(1-305aa) enhanced its binding to NS5B 
(Figure 1). DDX5(1-305aa) and DDX5(306-614aa) shall be referred to DDX5-N and 
DDX5-C in this study. 
Structural analyses of numerous DEAD-box RNA helicases revealed that they 
contain a central region comprising of two conserved domains, termed domains 1 and 2, 
flanked by highly variable N- and C- terminal sequences [19, 29-33].  Bio-informational 
analysis revealed that DDX5-N and DDX5-C contain domains 1 and 2 respectively (data 
not shown).   
 
Domain 1 of DDX5 is similar to that of other DEAD-box RNA helicases  
To gain further insights into the interaction between DDX5 and NS5B, DDX5-N 
and DDX5-C were expressed as N-terminal GST fusion. GST was removed with the 3C 
protease but five amino acids (GPLGS) remained fused to the N-terminal of these 
proteins. Purification of DDX5-C failed as the protein underwent degradation when 
expressed in Escherichia coli (data not shown).  Purification of DDX5-N was successful 
and crystallization trials were performed.  GST-pull down assay was also performed and 
the results showed that DDX5-N interacts with NS5B (supplementary Figure 1).  DDX5-
N was found to crystallize in space group I222 and the structure was solved by molecular 
replacement using the structure of domain 1 of DDX3X (PDB code: 2I4I) and refined to 
the crystallographic R-factor of 0.27 (Rfree 0.29). One molecule was identified in the 
asymmetric unit. Due to lack of density, residues 1-51 were not observed. The refinement 
statistics are shown in Table 1. 
DDX5-N contains eight centrally located -sheets packed against nine -helices 
(Figure 2).  A structure-homology search on the Dali server (www.ebi.ac.uk/dali) reveals 
a high degree of similarity of domain 1 of DDX5 (residues 79-303) with the equivalent 
domain in human DDX3X [19], drosophila VASA [32] and eukaryotic initiation factor 
4A-I (eIF4a) [30] with a root mean square difference (rmsd) of 1.4 Å, 1.7 Å and 1.9 Å 
respectively.  Structural-based sequence alignment revealed that residues 52-78 of 
DDX5-N form part of the NTR whereas residues 79-303 correspond to conserved domain 
1 (Figure 3).  Residues 52-78 of NTR contain a loop and an α-helix whereas the 
conserved domain 1 displays a RecA-like structure (Figure 3).   
It is clear that domain 1 of DDX5 contains many typical features found in the 
structures of other DEAD box helicases.  For example, the conserved motifs, Q, I 
(Walker A), II (Walker B, DEAD box), Ia, Ib, and III, in domain 1 of DDX5 superimpose 
with the corresponding regions in DDX3X (Figure 4).  The only difference is in the P-
loop (found in motif I) because DDX3X is in complex with AMP while DDX5-N is in 
the apo form.  In addition, DDX3X has an insertion between the P-loop and the RNA-
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binding motif Ia that forms a helix. It has been suggested this insertion helix is involved 
in RNA-binding and positioning [19]. This helix is not present in DDX5 (Figure 4). 
 Recently, the structure of domain 1 of DDX5 in complex with ADP was 
determined to a resolution of 2.6 Å ([33], PDB code; 3fe2). Structural analyses reveal 
residues in the Q motif make contact with the adenine moiety of the nucleotide, whereas 
phosphate moiety makes contact with the P-loop in motif I [33]. Superimposition of the 
apo and bound form reveals a rmsd of 1.2 Å. Overall, small changes are observed upon 
ADP binding with the exception of the P-loop. Upon ADP binding, the P-loop shifts by 
3.4 Å from the apo form (Figure 5). It is not possible to compare the features in NTR of 
the two forms because the NTR is absent from the protein used to solve the structure of 
ADP-bound DDX5 [33]. 
 
The ATP binding site of DDX5-N is not essential for the interaction with NS5B  
The crystal structure of DDX5-N showed that there is no nucleotide in the 
ADP/ATP binding site. In order to determine if the ATP binding site of DDX5-N is 
important for the interaction between DDX5-N and NS5B in Huh-7 cells, co-
immunoprecipitation experiments were performed to determine the interaction of two 
DDX5 substitution mutants (K144N and D248N) with NS5B.  Previous study has shown 
that the K144N substitution abolished ATP-binding while substitution within the DEAD-
box did not have any effect on ATP-binding [34].  The DDX5-N(K144N) substitution 
mutant bound NS5B to a similar extent as DDX5-N suggesting that ATP binding is not 
essential for the interaction (Figure 6).  The DDX5-N(D248N) substitution mutant also 
showed similar binding to NS5B, suggesting that the DEAD-box is not essential for the 
interaction. 
 
The flexible region in the NTR of DDX5-N auto-inhibits its interaction with NS5B  
The co-immunoprecipitation experiments showed that DDX5-NΔ60 (i.e. 
DDX5(61-305aa)) binds NS5B stronger than DDX5-N (Figure 1), suggesting that the 
NTR of DDX5-N can auto-inhibit its interaction with NS5B. However, due to disorder, 
only part of the NTR region (52-78) was observed in our crystal structure. This region 
forms an extensive loop and supplements the core with an additional -helix (Figure 2).  
Unfortunately, the crystal structure does not reveal any contact between the NTR and the 
rest of DDX5-N. This does not rule out that the NTR can fold back on the rest of DDX5-
N, but rather is a reflection of the highly flexible nature of the NTR and the possibly 
highly dynamic nature of the interaction. Hence, to further investigate the structural 
elements in NTR that are involved in the auto-inhibition, coimmunoprecipitation 
experiments were performed using DDX5-N and 3 mutants of DDX5-N. The first mutant 
is DDX5-NΔ60 in which the N terminal part of the NTR has been deleted, but the helix 
in the NTR remains intact. The second mutant is DDX5-NΔ78 where the entire NTR has 
been deleted. The third mutant is DDX5-NΔ70-78 where the helix in the NTR has been 
deleted but the flexible first 50 residues and the extended loop remains intact (Figure 
7A). 
Consistent with the results shown in Figure 1, DDX5-NΔ60aa and DDX5-
NΔ78aa showed significantly higher binding to NS5B than DDX5-N (Figure 7B), 
indicating that the auto-inhibition is abolished when part or the complete NTR is deleted. 
The internal deletion mutant DDX5-NΔ70-78aa also binds strongly to NS5B (Figure 7B), 
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indicating that residues 1-69 cannot cause auto-inhibition in the absence of the helix 
formed by residues 70-78. This suggests that this helix may bring the flexible 1-69 
residues of NTR close to the NS5B binding site in DDX5-N, presumably within residues 
79-305. Consistently, in vitro translated DDX5(61-614aa) was pulled down  by DDX5(1-
80aa) fused to GST but not by GST alone (Figure 8). 
 
DDX5-NΔ60 interacts directly with NS5B  
 In order to rule out that the possibility that the auto-inhibition by the NTR of 
DDX5-N is mediated through the interaction with a third protein, CD and NMR 
experiments were next performed to characterize the solution conformation of DDX5-
NΔ60 and its in vitro interaction with NS5B.  Firstly, NS5B protein was first expressed 
and assessed for its solution conformation.  As seen in Figure 9A, NS5B has a far-UV 
CD spectrum typical of a helix-dominant protein, with two large negative signals at ~208 
nm and 222 nm respectively, consistent with its three dimensional structure. The very 
large positive signal at ~192 nm indicates that it also has a tight tertiary packing. A one-
dimensional 1H NMR spectrum for NS5B (Figure 9B) was also collected but the 
resonance peaks are very broad mostly due to the short transverse relaxation time (T2) 
resulting from its very large size.  
 Secondly, DDX5-NΔ60 was purified and subjected to far-UV CD spectroscopy 
(Figure 9A). The results show that DDX5-NΔ60 has a helix-dominant structure with tight 
tertiary packing, in agreement with its three dimensional structure determined in the 
present study. Consistent with the CD results, the one-dimensional 1H NMR spectrum of 
DDX5-NΔ60 shows a large dispersion of the amide protons signals as well as many very 
up-field signals (Figure 9D), indicating that DDX5-NΔ60 is well folded. However, also 
likely due to its relatively large size, its proton resonance signals are broad. This is 
further confirmed by its two-dimensional 1H-15N HSQC spectrum acquired on a 15N-
labeled DDX5-NΔ60 sample (Figure 9C), in which although both 1H and 15N spectral 
dispersion are large, many peaks from amide protons are too broad to be detectable.  
 As a consequence, the direct binding of DDX5-NΔ60 to NS5B was assessed by 
monitoring the one-dimensional 1H NMR spectra of DDX5-NΔ60 in the absence or 
presence of NS5B at molar ratios of 1:1, 1:2 and 1:3 (Figure 9E). Interestingly, addition 
of NS5B into DDX5-NΔ60 at a molar ratio of 1:1 (DDX5:NS5B) caused a significant 
decrease of resonance intensities and resulted in resonance broadenings (Figure 9E). 
Furthermore, no large change was further detected for the NMR spectra when more 
NS5B was added (at molar ratios of 1:2 and 1:3). This clearly indicates that DDX5-NΔ60 
binds to NS5B to form a tight complex because the complex formation was almost 
completed at a molar ratio of 1:1 (DDX5:NS5B). However, the very large molecular 
weight of the tight complex will lead to a dramatic shortening of T2, and consequently 
the NMR signals become very broad, thus leading to the significant reduction of the 
signal intensity. If no interaction existed between DDX5-NΔ60 and NS5B, the NMR 
spectrum of the mixture would be a simple addition of two separate spectra which should 
have resonance intensities larger than each spectrum (Figure 9F). However, this is not the 
case, demonstrating that DDX5-NΔ60 does interact directly with NS5B.  
Further biophysical characterization of the interaction between DDX5-NΔ60 and 
NS5B was hindered by the fact that the DDX5-NΔ60-NS5B complex appears to be prone 
to aggregation. Although during the NMR titrations, no visible aggregation was observed, 
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the mixture sample would precipitate overnight. Indeed, in order to obtain 
thermodynamic binding parameters, isothermal titration calorimetry was performed with 
various protein concentrations but all the experiments failed because of sample 
precipitation. It is likely that the precipitation of the complex was accelerated by rapid 









Over the past decade, a growing number of DEAD-box RNA helicase structures 
have been determined [19, 29-33]. They contain a central region comprising of two 
conserved domains, termed domains 1 and 2, flanked by highly variable N- and C- 
terminal sequences. Comparison of known structures of domain 1 and 2 reveal they have 
a fold belonging to the RecA super family, where five -strands are surrounded by five 
-helices [35]. We have previously shown that DDX5 interacts with NS5B and that the C 
terminal of NS5B is essential for this interaction [5].  Coimmunoprecipitation 
experiments showed there are two independent NS5B binding sites in DDX5, one in 
DDX5-N (corresponding to residues 1 to 305 of DDX5) and the other in DDX5-C 
(corresponding to residues 306 to 614 of DDX5) (Figure 1).  Interestingly, DDX5-N and 
DDX5-C contain domain 1 and 2 respectively.   
The crystal structure of the apo form of DDX5-N (residues 52-304) was solved 
and it reveals that domain 1 of DDX5 contains many typical features found in the 
structures of other DEAD box helicases (Figures 2 and 3).  Generally, the P-loop in 
DEAD-box helicases adapts either an open or closed conformation. The open 
conformation, typically found in NTPases whether nucleotide bound or not, is observed 
in the nucleotide bound form of the DEAD-box helicase eIF4A [30] and 56-kDa U2AF-
associated protein UAP56 [31] whereas the closed conformation is observed in the 
unbound structures of eIF4A [30],  UAP56 [31], and BSTDead [29].  In DDX5-N, the P-
loop clearly adopts an open conformation in the presence of bound nucleotide whereas 
the apo form is in a closed conformation (Figures 4 and 5).  However, neither the ATP 
binding site nor DEAD motif in DDX5-N is required for its interaction with NS5B 
(Figure 6).   
The NTRs of DEAD-box helicases are highly variable and there is limited 
structural information [6-7].  For DDX5-N, no density was observed for residues 1-51 
within the NTR. Analysis, using the protein disorder server RONN [36], predicted this 
region to be disordered as is observed with other DEAD-box helicases.  The remaining 
part of the NTR (residues 52 to 78) comprises of a loop and an α-helix located before 
domain 1.  To our knowledge, this is only the second report of structural elements in the 
NTR of DEAD-box RNA helicases as most of the structures of DEAD-box RNA 
helicases were obtained using proteins expressed without the NTR. Indeed, the recently 
solved structure of ADP-bound DDX5 only consists of domain 1 ([33], PDB code; 3fe2). 
The first report documented an α-helix in the NTR of DDX19 which inserts between 
domains 1 and 2 to inhibit ATP hydrolysis unless it is displaced by RNA binding [37]. 
Interestingly, the NTR of DDX5-N inhibits its interaction with NS5B (Figure 7).  
The -helix in NTR is essential for this auto-inhibition and seems to mediate the 
interaction between the highly flexible 1-51 residues in NTR and NS5B binding site in 
DDX5-N (Figures 7 and 8), presumably located within residues 79-305.  Furthermore, 
DDX5(1-80aa) can bind directly to DDX5(61-614aa) (Figure 8), thus providing further 
evidence that the flexible NTR of DDX5 folds back to interact with the NS5B binding 
site.  Consistently, NMR investigations reveal that there is indeed a direct interaction 
between DDX5-NΔ60 and NS5B in vitro (Figure 9). 
Our results suggest that the DDX5-N and DDX5-C interact with NS5B 
independently. The high-resolution three-dimensional structure of the apo form of 
DDX5-N was solved and provides a basis for future studies to define the precise role of 
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DDX5 during HCV infection.  Crystallization of full-length DDX5 and the DDX5-NS5B 
complex is also actively being pursued. Our data also reveal that the interaction between 
DDX5-N and NS5B is auto-inhibited by the highly flexible NTR of DDX5-N and the α-
helix formed by amino acids 70-78 is necessary for the inhibition to occur. It is expected 
that solving the structure of full-length DDX5 can help us ascertain whether this α-helix 
can insert between domains 1 and 2 as has been observed for DDX19 [37].  
Recent studies revealed that several DEAD-box RNA helicases, like DDX3, 
rck/p54 and RNA helicase A, are required for HCV RNA replication [38-40]. It is 
integrating that multiple DEAD-box RNA helicases are important for HCV replication 
and further studies are warranted to determine if they are involved in the same step(s) of 
the viral life-cycle. It is also possible that these host proteins are involved in more than 
one viral-host interaction. For example, DDX3 not only binds the HCV core protein, but 
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Table 1. Data Collection and Refinement Statistics 
Data Collection 
Wavelength (Å)                    0.99 
Resolution (Å)a                    25-2.7 (2.8-2.7) 
Space group                     I222    
Unit-cell parameters (Å, o)                              a = 66.18, b = 73.80, c = 104.00 
                                                                                                   =β=γ=90 
Observed reflectionsa                    42651 (4083)  
Unique reflectionsa                    7229 (704) 
Completeness (%)a                    99.8 (99.9) 
I/(I)a                                                                                         21.5 (2.7) 
Rmerge (%)a                     8.5 (48.3) 
Multiplicitya                     5.9 (5.8) 
Refinement Statistics 
R     (%)                                                                                      27                                                  
Rfree (%)                                                                                      29 
Rms deviation 
Bond lengths (Å)                                                                        0.008 
Bond angles (o)                                                                           1.6 
Model Quality (Ramachandran Plot)b 
Residues in most favoured regions (%)                                      82.3 
Residues in additional allowed regions (%)                               16.4 
Residues in generously allowed and disallowed regions (%)     0.5 
a Values in brackets indicate values in the highest resolution shell 




Figure 1. Interaction of HCV NS5B with full-length and deletion mutants of DDX5 as 
determined by coimmunoprecipitation experiments. Huh-7 cells were transfected with 
cDNA constructs for expressing myc-tagged GST (negative control), myc-tagged full-
length or deletion mutants of DDX5 and flag-tagged HCV NS5B. The cells were 
harvested at 16 h posttransfection, lysed, and subjected to immunoprecipitation with anti-
myc polyclonal antibody and protein A agarose beads. The amount of flag-tagged NS5B 
that coimmunoprecipitated (co-IP) with the myc-tagged proteins was determined by 
Western blot analysis with an anti-flag monoclonal antibody (top panel). The protein 
marked with an asterisk represents the heavy chain of the antibody used for 
immunoprecipitation (top panel). The amounts of myc-tagged and flag-tagged proteins in 
the lysates before co-IP were determined by subjecting aliquots of the lysates to Western 
blot analysis (WB, middle and bottom panels).  
 
 
Figure 2. Structural features of DDX5-N. A ribbon representation of the structure of 
DDX5-N (residues 52-304). Residues 52-78 (Orange) correspond to a segment from the 
N-terminal variable region (NTR) whereas the remaining residues 79-304 correspond to 
the conserved domain 1. Conserved motifs are illustrated accordingly. All structural 
figures were generated with PyMOL (http://pymol.sourceforge.net/). 
 
Figure 3. Structure based sequence alignment of DEAD-box helicases DDX5, DDX3X, 
VASA and eIF4a. DEAD-box helicases contain 2 conserved covalently linked globular 
domains, termed domain1 and 2, flanked by highly variable N and C terminal sequences. 
Only part of the highly variable N and C terminal sequences is shown.  Identical residues 
are shown in white letters with filled boxes while similar residues are boxed. The 
conserved domains harbor highly conserved motifs.  Domain 1 contains conserved motifs 
Q, I, II, Ia, Ib and III, whereas domain 2 possess motif IV, V and VI. The conserved 
motifs are highlighted. Secondary structure elements of DDX5 are shown. 
 
Figure 4. Structural comparison of domain 1 of DDX5 and DDX3X. The apo form of 
DDX5 is highlighted in green and red whereas the AMP bound form of DDX3X is in 
blue. The regions highlighted in red (a and b) show the major difference between DDX5 
and DDX3X. The P-loop in DDX5 is in a closed conformation (a). Furthermore, DDX5 
lacks a 10 amino acid insertion, which forms a helix between the P-loop and motif Ia in 
DDX3X (b). Despite these differences the main chain atoms of domain 1 of both 
helicases superimposed with an rmsd of 1.4 Å.  
 
Figure 5. Structural comparison of the apo and ADP bound forms of domain 1 of DDX5. 
Stereo view of apo (green) and ADP bound forms of DDX5 (pale blue). The P-loop 
(found in motif I) for the ADP-bound form is highlighted in purple. The P-loop 
undergoes significant conformation changes upon nucleotide binding. The bound ADP is 
shown in sticks. 
 
Figure 6. Co-immunoprecipitation of NS5B with DDX5-N containing mutation in the 
ATP binding or ATP hydrolysis site. Huh-7 cells were transfected with cDNA constructs 
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for expressing myc-tagged GST (negative control), myc-tagged DDX5-N or myc-tagged 
DDX5-N containing substitution mutation and flag-tagged HCV NS5B. The cells were 
harvested at 16 h posttransfection, lysed, and subjected to immunoprecipitation with anti-
myc polyclonal antibody and protein A agarose beads. The amount of flag-tagged NS5B 
that coimmunoprecipitated (co-IP) with the myc-tagged proteins was determined by 
Western blot analysis with an anti-flag monoclonal antibody (top panel). The protein 
marked with an asterisk represents the heavy chain of the antibody used for 
immunoprecipitation (top panel). The amounts of myc-tagged and flag-tagged proteins in 
the lysates before co-IP were determined by subjecting aliquots of the lysates to Western 
blot analysis (WB, middle and bottom panels).  
 
Figure 7. Co-immunoprecipitation of NS5B with DDX5-N containing deletion mutation 
in N-terminal flanking region (NTR).  (A) A schematic diagram showing deletion 
mutants of DDX5-N with modifications in the NTR. The first 51 residues of the NTR are 
highly disordered, followed by an extended loop structure from 52-69 and an α-helix 
from amino acids 70-78. (B) Huh-7 cells were transfected with cDNA constructs for 
expressing myc-tagged GST (negative control), myc-tagged DDX5-N or myc-tagged 
DDX5-N containing deletion mutation in NTR and flag-tagged HCV NS5B. The cells 
were harvested at 16 h posttransfection, lysed, and subjected to immunoprecipitation with 
anti-myc polyclonal antibody and protein A agarose beads. The amount of flag-tagged 
NS5B that coimmunoprecipitated (co-IP) with the myc-tagged proteins was determined 
by Western blot analysis with an anti-flag monoclonal antibody (top panel). The protein 
marked with an asterisk represents the heavy chain of the antibody used for 
immunoprecipitation (top panel). The amounts of myc-tagged and flag-tagged proteins in 
the lysates before co-IP were determined by subjecting aliquots of the lysates to Western 
blot analysis (middle and bottom panels).  
 
Figure 8. GST pull-down of 35S-labelled DDX5(61-614aa) by GST-DDX5(1-80aa). 30 
μg of GST or GST-DDX5(1-80aa) were mixed with in vitro translated 35S-labelled 
DDX5(61-614aa). 30 μg of glutathione-sepharose bound fusion proteins used in the pull-
down assay were analyzed by SDS-polyacrylamide gel electrophoresis followed by 
Comassie blue staining to ascertain the purity of the proteins (top panel). An 
autoradiograph shows the amount of 35S-labeled DDX5(61-614aa) protein bound to GST-
DDX5(1-80aa) (lane 3) or GST alone (lane 2) (lower panel). One tenth of the binding 
input was loaded in lane 1 (bottom panel).  
 
Figure 9. Solution conformation of DDX5(61-305aa) and its binding with NS5B. (A) Far-
UV CD spectra of DDX5(61-305aa) (blue) and NS5B (red). (B) One-dimensional 1H 
NMR spectrum of NS5B. (C) Two-dimensional 1H-15N HSQC spectrum of the 15N-
labeled DDX5(61-305aa).  (D) One-dimensional 1H NMR spectrum of the DDX5(61-
305aa) protein. Red arrows are used to indicate several very up-field resonance peaks 
resulting from the tight tertiary packing. (E) Superimposition of one-dimensional 1H 
NMR spectra of the DDX5(61-305aa) in the absence of (blue) and in the presence of 
NS5B at molar ratios of 1:1 (black); 1:2 (green) and 1:3 (red) (DDX5:NS5B). (F) 
Superimposition of the simulated (black) and real (red) one-dimensional 1H NMR spectra 
of the mixture of DDX5(61-305aa) and NS5B at a molar ratio of 1:3 (DDX5:NS5B). The 
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simulated spectrum is generated by simply adding up two separate spectra of DDX5(61-
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Legend for supplementary Fig.1: GST pull-down of 35S-labelled NS5B by GST-DDX5-N.
30 μg of GST or GST-DDX5-N were mixed with in vitro translated 35S-labelled NS5B. 30 μg of glutathione-sepharose
bound fusion proteins used in the pull-down assay were analyzed by SDS-PAGE followed by Comassie blue staining to
ascertain the purity of the proteins (top panel). An autoradiograph shows the amount of 35S-labeled NS5B protein bound
to DDX5 N (lane 3) or GST alone (lane 2) (lower panel) One tenth of the binding input was loaded in lane 1 (lower panel)- . .
In contrast to the no or weak binding between DDX5-N and NS5B observed in co-IP experiments (Figure 1 and 7B), the
GST-tagged DDX5-N seems to bind NS5B in this GST pull-down experiment. There are two possible reasons for the
difference observed in GST pull-down and co-IP experiments. Firstly, the large GST tag of GST-DDX5-N may have
caused the NTR to loss its flexibility which is needed for the auto-inhibition effect. Secondly, the sensitivity of the GST
pull-down experiment may be higher given that the NS5B protein was isotopically labeled.
